Nisin, with its unique mode of action and potent antimicrobial
activity, serves as a remarkable inspiration for the design of novel
antibiotics. However, peptides possess inherent weaknesses, particularly
their susceptibility to proteolytic degradation, such as by trypsin,
which limits their broader applications. This led us to speculate
that natural variants of nisin produced by underexplored bacterial
species can potentially overcome these limitations. We carried out
genome mining of two Romboutsia sedimentorum strains, RC001 and RC002, leading to the discovery of rombocin A,
which is a 25 amino acid residue short nisin variant that is predicted
to have only four macrocycles compared to the known 31–35 amino
acids long nisin variants with five macrocycles. Using the nisin-controlled
expression system, we heterologously expressed fully modified and
functional rombocin A in Lactococcus lactis and demonstrated its selective antimicrobial activity against Listeria monocytogenes. Rombocin A uses a dual mode
of action involving lipid II binding activity and dissipation of the
membrane potential to kill target bacteria. Stability tests confirmed
its high stability at different pH values, temperatures, and in particular,
against enzymatic degradation. With its gene-encoded characteristic,
rombocin A is amenable to bioengineering to generate novel derivatives.
Further mutation studies led to the identification of rombocin K,
a mutant with enhanced bioactivity against L. monocytogenes. Our findings suggest that rombocin A and its bioengineered variant,
rombocin K, are promising candidates for development as food preservatives
or antibiotics against L. monocytogenes.